{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:08:08Z","timestamp":1793981288535,"version":"4.8.0"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,23]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Alterations in the gut microbiome usually occur in liver cirrhosis. Gut microbiome dysregulation damages the liver and accelerates the development of liver fibrosis. Probiotic treatment has gradually become a major method for improving the prognosis of liver cirrhosis and reducing its complications. However, alterations in the gut microbiome have revealed different results, and the therapeutic effects of various probiotics are inconsistent.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We searched the PubMed, Medline, EMBASE, ScienceDirect, and Cochrane databases up to August 2022 and conducted a systematic review and meta-analysis of 17 relevant studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The counts of <jats:italic toggle=\"yes\">Enterobacter<\/jats:italic> (standardized mean difference [SMD] \u22121.79, 95% confidence interval [CI]: \u22123.08 to \u22120.49) and <jats:italic toggle=\"yes\">Enterococcus<\/jats:italic> (SMD \u22121.41, 95% CI: \u22122.26 to \u22120.55) increased significantly in patients with cirrhosis, while the counts of <jats:italic toggle=\"yes\">Lactobacillus<\/jats:italic> (SMD 0.63, 95% CI: 0.12\u20131.15) and <jats:italic toggle=\"yes\">Bifidobacterium<\/jats:italic> (SMD 0.44, 95% CI: 0.12\u20130.77) decreased significantly. Blood ammonia (weighted mean difference [WMD] 14.61, 95% CI: 7.84\u201321.37) and the incidence of hepatic encephalopathy (WMD 0.40, 95% CI: 0.27\u20130.61) were significantly decreased in the probiotic group. As for mortality (MD 0.75, 95% CI: 0.48\u20131.16) and the incidence of spontaneous bacterial peritonitis (WMD \u22120.02, 95% CI: \u22120.07 to 0.03), no significant differences were found between the probiotic and placebo groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>In summary, the gut microbiome in cirrhosis manifests as decreased counts of <jats:italic toggle=\"yes\">Lactobacillus<\/jats:italic> and <jats:italic toggle=\"yes\">Bifidobacterium<\/jats:italic> and increased counts of <jats:italic toggle=\"yes\">Enterobacter<\/jats:italic> and <jats:italic toggle=\"yes\">Enterococcus<\/jats:italic>. Targeted supplementation of probiotics in cirrhosis, including <jats:italic toggle=\"yes\">Lactobacillus<\/jats:italic> combined with <jats:italic toggle=\"yes\">Bifidobacterium<\/jats:italic> or <jats:italic toggle=\"yes\">Bifidobacterium<\/jats:italic> alone, can reduce blood ammonia and the incidence of hepatic encephalopathy. The effect is similar to that of lactulose, but it has no obvious effect on mortality and spontaneous bacterial peritonitis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032335","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T14:08:09Z","timestamp":1672150089000},"page":"e32335","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":34,"title":["Alterations of gut microbiome and effects of probiotic therapy in patients with liver cirrhosis: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4154-6734","authenticated-orcid":false,"given":"Long","family":"Huang","sequence":"first","affiliation":[{"name":"Department of No. 1 Surgery, The First Hospital Affiliated to Anhui University of Traditional Chinese Medicine, Hefei, Anhui Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsheng","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of No. 1 Surgery, The First Hospital Affiliated to Anhui University of Traditional Chinese Medicine, Hefei, Anhui Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of No. 1 Surgery, The First Hospital Affiliated to Anhui University of Traditional Chinese Medicine, Hefei, Anhui Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Zhen","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Second Hospital Affiliated to Anhui University of Traditional Chinese Medicine, Hefei, Anhui Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/liv.13317","article-title":"Thrombocytopenia in chronic liver disease.","volume":"37","author":"Peck-Radosavljevic","year":"2017","journal-title":"Liver Int"},{"key":"R2-20250504","first-page":"909","article-title":"Relationships between types of esophagogastric varices and systemic hemodynamics in patients with liver cirrhosis.","volume":"58","author":"Chikamori","year":"2011","journal-title":"Hepatogastroenterology"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MOG.0b013e328351d003","article-title":"Complications of cirrhosis.","volume":"28","author":"Rahimi","year":"2012","journal-title":"Curr Opin Gastroenterol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.emc.2009.04.005","article-title":"Hepatic encephalopathy.","volume":"27","author":"Eroglu","year":"2009","journal-title":"Emerg Med Clin North Am"},{"issue":"Suppl 1","key":"R5-20250504","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1746-6342.2006.03215.x","article-title":"Review article: the burden of hepatic encephalopathy.","volume":"25","author":"Poordad","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s12072-021-10221-7","article-title":"Dynamic assessments of hepatic encephalopathy and ammonia levels predict mortality in acute-on-chronic liver failure.","volume":"15","author":"Verma","year":"2021","journal-title":"Hepatol Int"},{"key":"R7-20250504","article-title":"The impact of the gut microbiome on extra-intestinal autoimmune diseases.","author":"Miyauchi","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2147\/JIR.S174982","article-title":"The role of inflammation in irritable bowel syndrome (IBS).","volume":"11","author":"Ng","year":"2018","journal-title":"J Inflamm Res"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/cei\/uxac057","article-title":"Gut microbiome and autoimmune disorders.","volume":"209","author":"Shaheen","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature13568","article-title":"Alterations of the human gut microbiome in liver cirrhosis.","volume":"513","author":"Qin","year":"2014","journal-title":"Nature"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1136\/gutjnl-2016-312729","article-title":"Gut microbiome and liver diseases.","volume":"65","author":"Tilg","year":"2016","journal-title":"Gut"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/MCO.0b013e32830a70bc","article-title":"Gastrointestinal tract in liver disease: which organ is sick?","volume":"11","author":"Norman","year":"2008","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3390\/ijms22010199","article-title":"The role of the gut microbiome in liver cirrhosis treatment.","volume":"22","author":"Lee","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1 Suppl","key":"R14-20250504","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0002-9270(99)00806-0","article-title":"Probiotics and gastrointestinal health.","volume":"95","author":"Gorbach","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"666","DOI":"10.5009\/gnl20032","article-title":"Leaky gut and gut-liver axis in liver cirrhosis: clinical studies update.","volume":"15","author":"Fukui","year":"2021","journal-title":"Gut Liver"},{"key":"R16-20250504","first-page":"25","article-title":"Effects of probiotics on intestinal flora, inflammation and degree of liver cirrhosis in rats with liver cirrhosis by regulating Wnt\/\u03b2-catenin signaling pathway.","volume":"35","author":"Feng","year":"2021","journal-title":"J Biol Regul Homeost Agents"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/liv.13005","article-title":"Probiotics are helpful in hepatic encephalopathy: a meta-analysis of randomized trials.","volume":"36","author":"Saab","year":"2015","journal-title":"Liver Int"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/17474124.2018.1481747","article-title":"Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications.","volume":"12","author":"Ponziani","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.gastro.2020.04.077","article-title":"Contribution of the intestinal microbiome and gut barrier to hepatic disorders.","volume":"159","author":"Chopyk","year":"2020","journal-title":"Gastroenterology"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/liv.13485","article-title":"Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls.","volume":"38","author":"Heidrich","year":"2017","journal-title":"Liver Int"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"111081","DOI":"10.1016\/j.nut.2020.111081","article-title":"Alterations of intestinal microbiota in liver cirrhosis with muscle wasting.","volume":"83","author":"Ren","year":"2020","journal-title":"Nutrition"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1038\/ajg.2013.221","article-title":"Large-scale survey of gut microbiota associated with MHE Via 16S rRNA-based pyrosequencing.","volume":"108","author":"Zhang","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"R23-20250504","first-page":"128","article-title":"A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy.","volume":"32","author":"Saji","year":"2011","journal-title":"Trop Gastroenterol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/j.1872-034X.2012.01015.x","article-title":"Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy.","volume":"42","author":"Holte","year":"2012","journal-title":"Hepatol Res"},{"key":"R25-20250504","first-page":"CD008716","article-title":"Probiotics for patients with hepatic encephalopathy.","author":"McGee","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"R26-20250504","first-page":"603","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis.","volume":"25","author":"Wells","year":"2011","journal-title":"Euro J Epidemiol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1443-9573.2004.00157.x","article-title":"Intestinal microflora in patients with liver cirrhosis.","volume":"5","author":"Zhao","year":"2004","journal-title":"Chin J Dig Dis"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00248-010-9801-8","article-title":"Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients.","volume":"61","author":"Lu","year":"2011","journal-title":"Microb Ecol"},{"key":"R31-20250504","first-page":"4082","article-title":"Correlation of liver function with intestinal flora, vitamin deficiency and IL-17A in patients with liver cirrhosis.","volume":"16","author":"Mou","year":"2018","journal-title":"Exp Ther Med"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00284-012-0105-8","article-title":"Comparison of the gut microbe profiles and numbers between patients with liver cirrhosis and healthy individuals.","volume":"65","author":"Liu","year":"2012","journal-title":"Curr Microbiol"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/ajg.2012.113","article-title":"Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy.","volume":"107","author":"Agrawal","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.nut.2010.01.006","article-title":"Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study.","volume":"27","author":"Pereg","year":"2011","journal-title":"Nutrition"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/apt.12695","article-title":"Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis.","volume":"39","author":"Bajaj","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/j.1572-0241.2008.01861.x","article-title":"Probiotic yogurt for the treatment of minimal hepatic encephalopathy.","volume":"103","author":"Bajaj","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.cgh.2013.11.006","article-title":"Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial.","volume":"12","author":"Lunia","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1007\/s10620-006-9687-y","article-title":"Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study.","volume":"52","author":"Malaguarnera","year":"2007","journal-title":"Dig Dis Sci"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MEG.0b013e328330a8d3","article-title":"Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy.","volume":"22","author":"Malaguarnera","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/MEG.0b013e3282f3e6f5","article-title":"An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy.","volume":"20","author":"Sharma","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/hep.20194","article-title":"Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis.","volume":"39","author":"Liu","year":"2004","journal-title":"Hepatology"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1053\/j.gastro.2014.08.031","article-title":"Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial.","volume":"147","author":"Dhiman","year":"2014","journal-title":"Gastroenterology"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/MEG.0b013e32834696f5","article-title":"A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.","volume":"23","author":"Mittal","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0168-8278(95)80309-2","article-title":"Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy.","volume":"23","author":"Loguercio","year":"1995","journal-title":"J Hepatol"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/MEG.0b013e3283537d61","article-title":"Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis: a double-blind placebo-controlled randomized-controlled trial.","volume":"24","author":"Pande","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.gastro.2020.08.054","article-title":"Alterations in gut microbiome in cirrhosis as assessed by quantitative metagenomics: relationship with acute-on-chronic liver failure and prognosis.","volume":"160","author":"Sol\u00e9","year":"2020","journal-title":"Gastroenterology"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.3748\/wjg.v24.i34.3813","article-title":"Clinical impact of microbiome in patients with decompensated cirrhosis.","volume":"24","author":"Oikonomou","year":"2018","journal-title":"World J Gastroenterol"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"e25535","DOI":"10.1097\/MD.0000000000025535","article-title":"The efficacy of a multistrain probiotic on cognitive function and risk of falls in patients with cirrhosis: a protocol for systematic review and meta-analysis.","volume":"100","author":"Wang","year":"2021","journal-title":"Medicine (Baltim)"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1080\/00365520801947074","article-title":"Small intestinal bacterial overgrowth.","volume":"43","author":"Rana","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"6729","DOI":"10.3390\/ijms22136729","article-title":"Probiotics, prebiotics and epithelial tight junctions: a promising approach to modulate intestinal barrier function.","volume":"22","author":"Rose","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"595759","DOI":"10.3389\/fcimb.2020.595759","article-title":"The role of intestinal bacteria and gut-brain axis in hepatic encephalopathy.","volume":"10","author":"Chen","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jhep.2013.12.019","article-title":"Altered profile of human gut microbiome is associated with cirrhosis and its complications.","volume":"60","author":"Bajaj","year":"2014","journal-title":"J Hepatol"},{"key":"R53-20250504","doi-asserted-by":"crossref","first-page":"108238","DOI":"10.1016\/j.pharmthera.2022.108238","article-title":"Bile acid metabolism and signaling, the microbiota, and metabolic disease.","volume":"237","author":"Cai","year":"2022","journal-title":"Pharmacol Ther"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.3390\/ijms23052896","article-title":"Overview of the importance of biotics in gut barrier integrity.","volume":"23","author":"Kocot","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R55-20250504","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.3748\/wjg.v17.i24.2890","article-title":"Probiotics in hepatology.","volume":"17","author":"Lata","year":"2011","journal-title":"World J Gastroenterol"},{"key":"R56-20250504","first-page":"1","article-title":"Food and gut originated bacteriocins involved in gut microbe-host interactions.","volume":"17","author":"Teng","year":"2022","journal-title":"Crit Rev Microbiol"},{"key":"R57-20250504","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3389\/fimmu.2017.01036","article-title":"The microbial metabolite butyrate induces expression of Th1-associated factors in CD4+ T cells.","volume":"8","author":"Kespohl","year":"2017","journal-title":"Front Immunol"},{"key":"R58-20250504","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.rvsc.2022.04.015","article-title":"Prevalence and antimicrobial susceptibility of Enterococcus spp. from urine of dogs and cats in northwestern Croatia.","volume":"151","author":"Tumpa","year":"2022","journal-title":"Res Vet Sci"},{"key":"R59-20250504","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jad.2017.11.063","article-title":"A meta-analysis of the use of probiotics to alleviate depressive symptoms.","volume":"228","author":"Ng","year":"2018","journal-title":"J Affect Disord"},{"key":"R60-20250504","first-page":"1","article-title":"Safety of probiotics used to reduce risk and prevent or treat disease.","volume":"200","author":"Hempel","year":"2011","journal-title":"Evid Rep Technol Assess (Full Rep)"},{"key":"R61-20250504","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jgh.15716","article-title":"What is unknown in using microbiota as a therapeutic?","volume":"37","author":"Sung","year":"2022","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:23:47Z","timestamp":1746336227000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":60,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032335","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]}}}